Arie Belldegrun - Jun 12, 2024 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jun 12, 2024
Transactions value $
$0
Form type
4
Date filed
6/14/2024, 04:26 PM
Previous filing
May 20, 2024
Next filing
Jun 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +105K +117.4% 195K Jun 12, 2024 Direct F1
holding DNA Class A Common Stock 500K Jun 12, 2024 By Bellco Legacy LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -105K -100% 0 Jun 12, 2024 Class A Common Stock 105K $0.00 Direct F1, F3
transaction DNA Restricted Stock Units Award $0 +433K $0.00 433K Jun 13, 2024 Class A Common Stock 433K $0.00 Direct F1, F4
transaction DNA Stock Option Award $0 +571K $0.00 571K Jun 13, 2024 Class A Common Stock 571K $0.46 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 Bellco Legacy LLC is owned and managed by trusts controlled by the Reporting Person and Rebecka Belldegrun.
F3 In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
F4 The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
F5 In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.